Author: gmp
-
Saskia De Smet
Saskia is sr laboratory technician at CellGENTherapies driven by a passion for cell therapy Proficient in GMP-compliant manufacturing , she is playing a key role in production of dendritic cells and T cell based products With more than 25 years of expertise in stem cell processing and over 15 years of experience in cell therapy,…
-
Pascal Van Der Meulen, eng.
Pascal is project manager with a deep understanding of various techniques in separation, product isolation and purification methods for downstream processing in the broad ATMP field. Highly driven by purity and yield, he is the ideal asset at CellGENTherapies for the development and scale up of the manufacturing processes. Pascal brings in more than 25…
-
Nele Lootens
Nele is quality manager. Driven by quality and regulatory standard and continuous improvement initiatives, she is the safeguard of the quality management system at CellGENTherapies. She is overseeing all aspects of quality assurance, including quality management system and risk analysis, guaranteeing processes consistently meet quality. Nele has more than twenty years of experience as quality…
-
Louise De la Mane, Apr.
Louise is qualified person & quality control manager at CellGENTherapies. Her critical thinking and decision making is an important asset for the GMP processes and activities. She is overseeing the GMP-compliant manufacturing of cell- and gene therapies for phase I/II clinical trials, as wel as the GMP-compliant production process for personalized mRNA vaccines, covering the…
-
Joline Ingels, PhD
Joline is the head of GMP manufacturing. Driven by a strong interest in human immunology and cell- & gene therapies, she is very dedicated is to bring novel therapies from bench to bedside. At CellGENTherapies, Joline functions as head of production overseeing the manufacturing of several types of ATMPs, including dendritic cell- and mRNA-LNP based…
-
Prof. dr. Bart Vandekerckhove
Bart is the director of the GMP facility. His passion is to bring exciting cutting-edge research to the clinic for the benefit of patients in need. As director of the GMP unit he initiated collaborations with several investigators to perform clinical studies testing advanced therapy medicinal product for lung cancer, liver cancer, stem cell transplantation,…
-
Meet us at European Society of Gene & Cell Therapy Congress 2025 at Sevilla in October 2025
The team of CellGENTherapies doesn’t want to miss the European Society of Gene & Cell Therapy Congress 2025 at Sevilla and will participate in the exhibition. Through its activities ESGCT seeks to stimulate further exchange of scientific knowledge and expertise, as well as promote collaboration between and within clinics, academic research and the pharmaceutical and…
-
CellGENTherapies attracted by VIB and KUL
CellGENTherapies is attracted by the VIB and the Katholieke Universiteit Leuven (Prof Dieter Lambrechts) to produce a lipid nanoparticle RNA cancer vaccine using the Galsome technology developed by Ghent Research Group on Nanomedicines (Prof Stefaan De Smedt and Dr Ine Lentacker) for a clinical trial in patients with hepatocellular carcinoma (PI prof Jeroen Dekervel, UZLeuven).…
-
Meet us at GATE partnering event
The team of the GMP unit CellGENTherapies was present at GATE partnering event on 25th april 2025 and had great discussions on capabilities of their GMP unit for advanced therapies. At the GATE partnering event, researchers from UGent, UZ Gent, imec and VIB present break-through research on topics of gene and cell therapy, and regenerative…
-
Grant for phase I clinical trial evaluating a personalized mRNA-LNP vaccine in NSCLC
Prof Bart Vandekerckhove, head of the GMP unit ‘CellGENTherapies’ of Ugent and UZ Gent, has received an important grant of €790K from ‘the Stichting Tegen Kanker (STK)’ and ‘Kom op tegen Kanker (KOTK)’, both Belgians associations funding research to improve cancer outcome. The grant will be used to setup a Phase I clinical trial of…